These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 8473090)

  • 41. Carcinoma of the prostate: reasons for endocrine treatment prior to symptomatic metastases.
    Chisholm GD
    Prog Clin Biol Res; 1990; 359():1-6; discussion 15-24. PubMed ID: 2284285
    [No Abstract]   [Full Text] [Related]  

  • 42. Cell proliferation, apoptosis and prognosis in patients with metastatic prostate cancer.
    Furuya Y; Kawauchi Y; Fuse H
    Anticancer Res; 2003; 23(1B):577-81. PubMed ID: 12680149
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Long term survival results in advanced prostate cancer treated with combined androgen blockade].
    Zhang SG; Wang YH; Ding Y; Wu Y
    Zhonghua Nan Ke Xue; 2005 Oct; 11(10):770-1, 774. PubMed ID: 16281513
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [What is the best strategy of hormonal therapy in the treatment of locally advanced prostate cancer?].
    Ehara H; Nakano M; Deguchi T
    Hinyokika Kiyo; 2006 Jun; 52(6):473-7. PubMed ID: 16848361
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Clinical study of endocrine therapy in stage B and C prostate cancer].
    Uei T; Okazaki H; Nakamura T; Katou N; Suzuki K; Yamanaka H
    Hinyokika Kiyo; 2003 Nov; 49(11):639-43. PubMed ID: 14719450
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Response of patients with advanced prostatic cancer to administration of somatostatin analog RC-160 (vapreotide) at the time of relapse.
    González-Barcena D; Schally AV; Vadillo-Buenfil M; Cortez-Morales A; Hernández L V; Cardenas-Cornejo I; Comaru-Schally AM
    Prostate; 2003 Aug; 56(3):183-91. PubMed ID: 12772187
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immediate versus deferred hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment: results of the randomized trial SAKK 08/88.
    Walsh PC
    J Urol; 2005 Sep; 174(3):929. PubMed ID: 16093992
    [No Abstract]   [Full Text] [Related]  

  • 48. Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer.
    Smith MR
    Urology; 2004 Apr; 63(4):742-5. PubMed ID: 15072892
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Adverse effects of androgen deprivation therapy on persistent genitourinary complications after carbon ion radiotherapy for prostate cancer.
    Ishikawa H; Tsuji H; Kamada T; Hirasawa N; Yanagi T; Mizoe JE; Akakura K; Suzuki H; Shimazaki J; Nakano T; Tsujii H
    Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):78-84. PubMed ID: 18456419
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
    Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
    Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Cancer of the prostate: subcapsular orchiectomy].
    Cukier J; Rivain T
    Bull Cancer; 1985; 72(6):543-8. PubMed ID: 4092105
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Current management of prostatic carcinoma.
    Bahnson RR; Catalona WJ
    Prim Care; 1985 Dec; 12(4):795-813. PubMed ID: 3909178
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of estrogen therapy on metastatic carcinoma of the prostate.
    Anikwe RM
    Int Surg; 1977 Oct; 62(10):532-6. PubMed ID: 591215
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Do radiotherapy and immediate orchiectomy yield comparable results as radical prostatectomy, adjuvant irradiation and orchiectomy in patients with stage D1 of prostatic carcinoma?].
    Wiegel T
    Strahlenther Onkol; 1995 Aug; 171(8):480-1. PubMed ID: 7652675
    [No Abstract]   [Full Text] [Related]  

  • 55. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies.
    Byar DP; Corle DK
    NCI Monogr; 1988; (7):165-70. PubMed ID: 3050535
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Transrectal prostatosonography. Follow-up in prostate cancer therapy].
    Dolz M; Drakopoulos A; Aurich B; Frentzel-Beyme B
    Z Urol Nephrol; 1985 Sep; 78(9):465-74. PubMed ID: 3907200
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anandron (RU 23908) associated to surgical castration in previously untreated stage D prostate cancer: a multicenter comparative study of two doses of the drug and of a placebo.
    Brisset JM; Boccon-Gibod L; Botto H; Camey M; Cariou G; Duclos JM; Duval F; Gontiès D; Jorest R; Lamy L
    Prog Clin Biol Res; 1987; 243A():411-22. PubMed ID: 3309973
    [No Abstract]   [Full Text] [Related]  

  • 58. Carcinoma of the prostate in the elderly.
    Keegan GT; Coffield KS; Singh EO; Kroening PM
    Clin Geriatr Med; 1985 May; 1(2):359-71. PubMed ID: 3830370
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Why not neo-adjuvant therapy for prostatic carcinoma?
    Fair WR
    Prog Clin Biol Res; 1991; 370():305-12. PubMed ID: 1924464
    [No Abstract]   [Full Text] [Related]  

  • 60. Hormonal management of stage D carcinoma of the prostate.
    Trachtenberg J
    Urol Clin North Am; 1987 Nov; 14(4):685-94. PubMed ID: 2445092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.